Key insights
- Revolution Medicines' Chief Global Commercialization Officer sold $413k in shares under a pre-arranged 10b5-1 plan while exercising options for the same amount of shares at a lower price. Despite positive clinical trial data and a substantial stock surge, InvestingPro data suggests the stock is overvalued. The insider selling, coupled with valuation concerns, presents a mildly bearish signal.
Anthony Mancini, Chief Global Commercialization Officer at Revolution Medicines, Inc. (NASDAQ:RVMD), sold 3,120 shares of common stock for a total value of approximately $413,128 on April 27, 2026. The sales were executed pursuant to a 10b5-1 trading plan adopted on December 24, 2025.
The transactions involved multiple trades at varying prices:
1,671 shares were sold at prices ranging from $131.08 to $132.06.
1,049 shares were sold at prices ranging from $132.37 to $133.35.
400 shares were sold at prices ranging from $134.04 to $134.60.
On the same day, Mr. Mancini also acquired 3,120 shares of Revolution Medicines common stock by exercising stock options at a price of $33.62 per share, totaling approximately $104,894. These options are subject to a vesting schedule where 25% of the shares vest on the first-year anniversary from April 1, 2025, with subsequent monthly vesting over four years, contingent on his continued service.
Following these transactions, Mr. Mancini directly holds 54,400 shares of common stock, which includes 54,400 Restricted Stock Units. He also holds 109,230 stock options (right to buy).The insider sale comes as Revolution Medicines shares trade at $140.55, reflecting a remarkable 246% return over the past year, according to InvestingPro data. The stock has surged 142% over the last six months alone. However, InvestingPro analysis suggests the stock is currently overvalued relative to its Fair Value. For deeper insights, investors can access Revolution Medicines’ comprehensive Pro Research Report, one of 1,400+ available on InvestingPro.
In other recent news, Revolution Medicines presented updated clinical data from two Phase 1/2 trials evaluating daraxonrasib in metastatic pancreatic ductal adenocarcinoma. The trials showed a confirmed objective response rate of 58% with a notable progression-free survival rate of 84% at six months. Additionally, Revolution Medicines plans to present Phase 3 trial data for daraxonrasib at an upcoming ASCO meeting, highlighting statistically significant improvements in survival metrics. Mizuho raised its price target for Revolution Medicines to $185, citing an increased probability of success for daraxonrasib in pancreatic cancer treatment. Meanwhile, TD Cowen reiterated a Buy rating for the company, emphasizing its competitive stance in the pan-RAS therapy sector. The company also unveiled preclinical data on a new class of RAS inhibitors, RM-055, aimed at targeting mutant RAS proteins. These developments underscore Revolution Medicines’ ongoing research efforts and potential advancements in cancer treatment.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.